Portolan Capital Management, LLC Exelixis, Inc. Transaction History

Portolan Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$18.39 - $24.8 $2.69 Million - $3.62 Million	-146,168 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$20.67 - $26.94 $385,309 - $502,188	-18,641 Reduced 11.31%	146,168 $3.57 Million
Q2 2020 Aug 14, 2020	SELL	$16.46 - $27.42 $1.44 Million - $2.4 Million	-87,550 Reduced 34.69%	164,809 $3.91 Million
Q1 2020 May 14, 2020	SELL	$14.46 - $21.8 $761,781 - $1.15 Million	-52,682 Reduced 17.27%	252,359 $4.35 Million
Q4 2019 Feb 14, 2020	SELL	$15.15 - $18.89 $2.26 Million - $2.82 Million	-149,403 Reduced 32.88%	305,041 $5.38 Million
Q3 2019 Nov 14, 2019	SELL	$17.68 - $22.65 $1.52 Million - $1.95 Million	-86,146 Reduced 15.94%	454,444 $8.04 Million
Q2 2019 Aug 14, 2019	BUY	$18.93 - $24.75 $10.2 Million - $13.4 Million	540,590 New	540,590 $11.6 Million

565

251M

1.45M

1.13M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.9B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Portolan Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Portolan Capital Management, LLC with notifications on news.